We feel now is a pretty good time to analyse Atossa Therapeutics, Inc.'s ( NASDAQ:ATOS ) business as it appears the company may be on the cusp of a considerable accomplishment. Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The US$172m market-cap company's loss lessened since it announced a US$30m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$26m, as it approaches breakeven. As path to profitability is the topic on Atossa Therapeutics' investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.